


Advanced Therapeutics within Everyone's Reach

Celltrion IR Presentation

July & August 2025



Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only before the external audit is completed. The audit outcomes may cause some changes in this document.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.





CONTENTS

- 01. Business Overview
- 02. Global Commercial Update
- 03. Development and Production Strategy
- 04. Appendix


01

Business Overview

- Celltrion Group Growth Story
- 2Q25 Financial Highlights
- Biologics Global Market Sales
- Biologics Sales Breakdown (by Product)
- COGS Ratio Improvement Trend & Outlook

Celltrion Group Growth Story

Revenue Trend [Unit: KRW billion]



*The launch date for each product is based on the date it was first released in the global market

2Q25 Financial Highlights (Consolidated)



Sales and Profit Grow in Tandem via High-Margin Portfolio Shift Record-High Quarterly Operating Profit Since Merger

[Unit: KRW billion]

	2Q25	1Q25	QoQ	2Q24	YoY
Sales	961.5	841.9	+14.2%	874.7	+9.9%
Biologics	882.8	767.6	+15.0%	774.0	+14.1%
Non-Biologics	78.7	74.3	+5.9%	100.7	-21.8%
Operating Profit	242.5	149.4	+62.3%	72.5	+234.5%
OP Margin	25.2%	17.7%	+7.5%P	8.3%	+16.9%P

Sales Increased +9.9% YoY

- Biologics sales grew +14.1% YoY, driven by strong sales of high-margin young products that more than doubled YoY
- Non-biologics sales declined YoY due to the transfer of Takeda's primary care business, but with limited impact on profitability

OP Increased +234.5% YoY

- High-margin young products grew from 30% to 53% of sales, driving margin expansion
- Structural factors also supported margin improvement: completion of post-merger sales right amortization, high-cost inventory depletion, manufacturing cost improvement(TI) and completion of advanced products' development cost amortization


Biologics Global Market Sales




- Biologics revenue growth continues, led by young products: 2Q25 young portfolio sales reached KRW 468 billion (+101% YoY)
- Young portfolio accounted for 53% of 2Q25 sales; full-year contribution expected to exceed 60% in 2025

[Unit: KRW Billion]

Quarterly Comparison



Annual Forecast



* Advanced : Remsima, Truxima, Herzuma / Young : Remsima SC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, etc.


**2Q23, FY2023 : Pre-merger Celltrion Healthcare's sales

Biologics Sales (by Product)




- All three advanced products maintained stable sales:
(Base effect: Remsima saw a temporary supply increase in 2024 to address the decrease in safety stock amid strong demand and short-term manufacturing capacity constraints)
- Strong growth of young products offset fluctuations in advanced product sales, driving overall revenue and profit expansion
- Portfolio optimization centered on high-margin young products led to simultaneous revenue and profit growth

Advanced Products ▼ KRW126 bn




High-margin Young Products ▲ KRW 235 bn

[Unit: KRW Billion]



COGS Ratio Improvement Trend & Outlook

COGS Ratio Trend & Forecast Following Merger (Dec. 2023)



Key Drivers of COGS Improvement

1 Product Mix

- ✓ Higher portion of high-margin young products
- ✓ Further improvement expected as new products expand in 2H25

2 Merger Impact

- ✓ High-cost inventory mostly depleted, contributing to the reduction in the COGS

3 Manufacturing Cost

- ✓ DS outsourcing completed in 1Q25; all products now fully in-house
- ✓ TI versions in production for all advanced products (Remsima, Truxima, Herzuma)

4 R&D Amortization

- ✓ Herzuma amortization ended in 4Q24; Remsima to be complete in 3Q25, reducing development-related costs




02


Global Commercial Update

- Global Commercial Update

Continued strong presence across Europe and the U.S. sustaining leadership in the infliximab market



* Based on infliximab IV Market (Excluding SC) * Market share based on prescription volume
* Source: IQVIA




* Based on infliximab IV Market (Excluding SC) * Market share based on prescription volume
* Source: IQVIA, Symphony Health


Truxima (Rituximab) & Herzuma (Trastuzumab)



Truxima’s M/S remains stable in both Europe and the U.S.
Herzuma maintains No.1 biosimilar position in Europe and strong market dominance in Japan



* Market share based on prescription volume
* Source: IQVIA, Symphony Health





* Market share based on prescription volume
* Source: IQVIA

Remsima SC & Zymfentra (Infliximab SC)





Remsima SC hit a record 27% M/S in EU5, uptake expanding across non-EU5 countries
Zymfentra prescriptions steadily rising in the U.S., indicating gradual demand expansion




1. Based on EU5 Infliximab market
* Data based on SC dose-adjusted prescription volume * Source: IQVIA

* Source: IQVIA SMART WSP(Weekly Sales Perspectives)

Both Yuflyma and Vegzelma delivered solid global performance, with 1.7–2x YoY sales growth



Steqeyma quarterly sales surpassed KRW 30B within 6M of launch via bundled autoimmune portfolio
Stoboclo·Osenvelt signed U.S. hospital supply deals at launch, driving prescription expansion



Global Status of Stoboclo·Osenvelt

Launch Status

U.S. Launch in July
Launched with a High WAC price, 5% lower than the U.S. original (Full-label)

European launch expected in 2H25

Initial Results

Supply contracts secured with major U.S. hospital group

Strong sales momentum anticipated in 2H25

03

Development and Production Strategy

- Biosimilar R&D Update
- Upcoming Launches
- Novel Drug Pipeline
- IND Submission Timelines for Novel Drug Pipeline
- U.S. Tariff Response Strategy

Biosimilar R&D Update


R&D Progress

Indication	Pipeline	Global Market Size (2024)	R&D Status	
			US	EU
Autoimmune Diseases	 SteQeyma ustekinumab	\$21.7bn	Approved (Dec. 2024)	Approved (Aug. 2024)
	 Avtozma tocilizumab	\$3.5bn	Approved (Jan. 2025)	Approved (Feb. 2025)
	CT-P53 (biosimilar of OCREVUS®)	\$8.2bn	In Phase 3 Clinical Trial	
	CT-P55 (biosimilar of COSENTYX®)	\$9.9bn	In Phase 3 Clinical Trial	
AMD ¹	 Eydenzelt aflibercept	\$9.5bn	BLA under review (23.06)	Approved (Feb. 2025)
Asthma, CIU ²	 Omlyclo omalizumab	\$5.0bn	Approved (Mar. 2025)	Approved (May. 2024)
Osteoporosis	 Stoboclo denosumab  Osenvelt denosumab	\$7.4bn	Approved (Mar. 2025)	Approved (Feb. 2025)
NSCLC ³	CT-P51 (biosimilar of KEYTRUDA®)	\$32.7bn	In Phase 3 Clinical Trial	
Multiple Myeloma	CT-P44 (biosimilar of DARZALEX®)	\$11.7bn	In Phase 3 Clinical Trial	

1. AMD : Age-related Macular Degeneration 2. CIU : Chronic Idiopathic Urticaria 3. NSCLC : Non-Small Cell Lung Cancer

* Source : IQVIA, J&J(DARZALEX), Regeneron(EYLEA)

Portfolio Status




Upcoming Launches

Upcoming Launches

To be launched in 2H25


Molecule	Product	Timeline	
		EU	US
Ustekinumab	 SteQeyma ustekinumab	Completed	Completed
Omalizumab	 Omlyclo omalizumab	2025.2H	Settlement confirmed (date undisclosed)
Aflibercept	 Eydenzelt aflibercept	2025.2H	TBD
Denosumab	 Stoboclo denosumab  Osenvelt denosumab	2025.2H	Completed
Tocilizumab	 Avtozma tocilizumab	2025.2H	2025.2H

Target Market Expansion



* Sources: IQVIA, Regeneron(Eylea)


Novel Drug Pipeline : ADC & Multi-specific Antibodies



IND Submission Timelines for Novel Drug Pipeline




● ADC ● Multispecific Antibody --- IND Submission



1. NSCLC: Non-Small Cell Lung Cancer

U.S. Tariff Response Updates

Aiming to Fully Eliminate Tariff Exposure: Reinforcing U.S. Supply and Production Capabilities





04

Appendix

- Earnings Summary
- Quarterly Sales Mix

Earnings Summary (Consolidated)



Quarterly

	2Q24	3Q24	4Q24	1Q25	2Q25
Sales	875	882	1,064	842	962
Cost of Sales	507	419	520	399	417
Gross Profit	368	463	544	443	544
GP Margin	42.1%	52.5%	51.1%	52.6%	56.6%
SG&A	295	256	347	293	302
- R&D Expenses	36	53	61	56	46
Operating Profit	73	208	196	149	243
OP Margin	8.3%	23.6%	18.5%	17.7%	25.2%
Other Non-operating Profit/Loss*	39	(19)	80	48	(166)
Financial Income/Loss	(7)	(11)	(4)	(2)	(25)
Profit before Income Tax	104	178	274	195	52
Net Profit	78	84	236	108	63
NP Margin	9.0%	9.5%	22.2%	12.9%	6.6%

* Other non-operation profit/loss includes the net gain/loss on equity method valuation, etc.

* Figures are rounded to the nearest KRW 10 billion; minor discrepancies may occur due to rounding

Six Months (Cumulative)

[Unit: KRW billion]

	2024	2025	YoY
	1,612	1,803	11.8%
	937	816	-12.9%
	675	987	46.4%
	41.8%	54.7%	12.9%p
	587	595	1.4%
	86	103	19.8%
	88	392	345.5%
	5.5%	21.7%	16.2%p
	45	(117)	-360.0%
	(9)	(27)	-200.0%
	124	248	100.0%
	99	172	73.7%
	6.2%	9.5%	3.3%p

Quarterly Sales Mix

Quarterly

	2Q24	3Q24	4Q24	1Q25	2Q25
Sales	875	882	1,064	842	962
Biologics	774	810	873	768	883
Advanced Products	541	468	470	420	415
Remsima	363	317	289	238	261
Truxima	115	102	132	129	103
Herzuma	62	49	49	54	51
Young Products	233	342	403	347	468
Remsima SC	111	171	170	135	161
Yuflyma	80	94	108	118	137
Vegzelma	40	69	77	58	80
Zymfentra	2	6	28	13	23
Steqeyma	-	2	18	21	35
Others	-	-	2	1	32
Non-Biologics	101	72	190	74	79
CT Pharm/Chemical	95	65	79	68	73
CMO	-	-	106	-	-
Others	6	7	5	6	6

Six Months (Cumulative)

[Unit: KRW billion]

	2024	2025	YoY
Sales	1,612	1,803	11.8%
Biologics	1,425	1,650	15.8%
Advanced Products	978	835	-14.6%
Remsima	663	499	-24.7%
Truxima	216	231	6.9%
Herzuma	99	105	6.1%
Young Products	447	815	82.3%
Remsima SC	224	296	32.1%
Yuflyma	147	255	73.5%
Vegzelma	75	139	85.3%
Zymfentra	2	36	1,700.0%
Steqeyma	-	57	-
Others	-	32	-
Non-Biologics	187	153	-18.2%
CT Pharm/Chemical	175	140	-20.0%
CMO	-	-	-
Others	11	13	18.2%

* Figures are rounded to the nearest KRW 10 billion; minor discrepancies may occur due to rounding

Advanced Therapeutics within Everyone's Reach

Thank you